1. Home
  2. CGEN vs PTLE Comparison

CGEN vs PTLE Comparison

Compare CGEN & PTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • PTLE
  • Stock Information
  • Founded
  • CGEN 1993
  • PTLE 2013
  • Country
  • CGEN Israel
  • PTLE Singapore
  • Employees
  • CGEN N/A
  • PTLE N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • PTLE Oil Refining/Marketing
  • Sector
  • CGEN Health Care
  • PTLE Energy
  • Exchange
  • CGEN Nasdaq
  • PTLE Nasdaq
  • Market Cap
  • CGEN 142.4M
  • PTLE 130.7M
  • IPO Year
  • CGEN 2000
  • PTLE 2024
  • Fundamental
  • Price
  • CGEN $2.25
  • PTLE $2.98
  • Analyst Decision
  • CGEN Strong Buy
  • PTLE
  • Analyst Count
  • CGEN 1
  • PTLE 0
  • Target Price
  • CGEN $4.00
  • PTLE N/A
  • AVG Volume (30 Days)
  • CGEN 898.9K
  • PTLE 1.9M
  • Earning Date
  • CGEN 03-04-2025
  • PTLE 02-21-2025
  • Dividend Yield
  • CGEN N/A
  • PTLE N/A
  • EPS Growth
  • CGEN N/A
  • PTLE N/A
  • EPS
  • CGEN 0.02
  • PTLE 0.03
  • Revenue
  • CGEN $59,852,000.00
  • PTLE $108,126,091.00
  • Revenue This Year
  • CGEN $57.27
  • PTLE N/A
  • Revenue Next Year
  • CGEN N/A
  • PTLE N/A
  • P/E Ratio
  • CGEN $125.59
  • PTLE $92.34
  • Revenue Growth
  • CGEN 698.03
  • PTLE 36.47
  • 52 Week Low
  • CGEN $1.35
  • PTLE $2.01
  • 52 Week High
  • CGEN $3.03
  • PTLE $15.78
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 81.70
  • PTLE N/A
  • Support Level
  • CGEN $1.92
  • PTLE N/A
  • Resistance Level
  • CGEN $2.16
  • PTLE N/A
  • Average True Range (ATR)
  • CGEN 0.15
  • PTLE 0.00
  • MACD
  • CGEN 0.07
  • PTLE 0.00
  • Stochastic Oscillator
  • CGEN 88.90
  • PTLE 0.00

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About PTLE PTL LTD Ordinary Shares

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, primarily serving the Asia Pacific market. As a bunker facilitator, the Group's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers in a timely manner; and handling disputes, mainly in relation to quality and quantity issues on marine fuel, if any.

Share on Social Networks: